Month: August 2024

Opthea Reports Full-Year Financial Results and Business Updates

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in preparation for regulatory filing and launch of sozinibercept MELBOURNE, Australia, and PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) —  Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced financial results for the twelve months ended June 30, 2024, and highlighted recent corporate and clinical updates. “During the 2024 fiscal year, we made outstanding progress in advancing sozinibercept’s Phase 3 wet AMD program,” said Frederic Guerard,...

Continue reading

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Written by Customer Service on . Posted in Public Companies.

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days. About CG OncologyCG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential...

Continue reading

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Written by Customer Service on . Posted in Public Companies.

NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference in New York City, NY. Company management will host 1×1 meetings on Thursday, September 5, 2024, and Ian Somaiya, Chief Financial Officer, will participate in a fireside chat on Friday, September 6, 2024, at 10:00 a.m. ET; and Cantor Global...

Continue reading

Admiral Markets AS 2024 Unaudited 6 Months Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Admiral Markets AS 2024 Unaudited 6 Months Financial Results Despite the low volatility in the financial markets in the first half of 2024, Admiral Markets AS delivered increased trading revenues and positive EBITDA through effective cost control measures.    The Company’s net trading income increased by 21% to EUR 6.9 million (6M 2023: EUR 5.7 million). The Company’s operating expenses decreased by 29% to EUR 6.8 million (6M 2023: EUR 9.6 million). EBITDA was EUR 1.2 million (6M 2023: EUR -3.0 million). Net profit was EUR 0.9 million (6M 2023: EUR -3.9 million). Admirals voluntarily decided in April 2024 to temporarily suspend the onboarding of new customers for Admirals Europe Ltd. This decision is related to Admirals Europe Ltd’s efforts to comply with and adapt to the recommendations of the CySEC...

Continue reading

Admirals Group AS 2024 Unaudited 6 Months Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Admirals Group AS 2024 Unaudited 6 Months Financial Results  Despite the low volatility in the financial markets in the first half of 2024, Admiral Markets AS delivered increased trading revenues and positive EBITDA through effective cost control measures.  The Group’s net trading income increased by 4% to EUR 22.0 million (6M 2023: EUR 21.1 million).  The Group’s operating expenses decreased by 9% to EUR 22.9 million (6M 2023: EUR 25.2 million).  EBITDA was EUR 0.4 million (6M 2023: EUR -2.9 million).  Net loss was EUR -1.2 million (6M 2023: EUR -4.8 million).  Admirals voluntarily decided in April 2024 to temporarily suspend the onboarding of new customers for Admirals Europe Ltd. This decision is related to Admirals Europe Ltd’s efforts to comply with and adapt to the recommendations of the CySEC regulator and affects...

Continue reading

Registration of share capital increase in IDEX Biometrics 30 Aug 2024

Written by Customer Service on . Posted in Public Companies.

Reference is made to the notice on 29 August 2024 regarding settlement of a term payment on a convertible loan by issue of 9,123,333 shares at NOK 0.60 per share. The share capital has been registered and the shares will be delivered soonest. Following the issue, the company’s share capital is NOK 50,812,483.20 divided into 338,749,888 shares, each with a nominal value of NOK 0.15. For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: +47 918 00186 About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary...

Continue reading

Extraordinary General Meeting – Nykredit Realkredit A/S

Written by Customer Service on . Posted in Public Companies.

To Nasdaq Copenhagen Nykredit Realkredit A/S – Extraordinary General Meeting on 30. August 2024 At the Extraordinary General Meeting of Nykredit Realkredit A/S held on Friday 30 August 2024, a resolution passed by the Board of Directors to distribute dividend of DKK 2.200 billion was approved. Copenhagen, 30 August 2024 Nykredit Realkredit A/SBoard of Directors ContactIf you have any questions, please contact Press Relations, tel +45 31 21 06 39. Attachment Extraordinary_General_Meeting_Nykredit Realkredit_A_S_2024-08-30_EN

Continue reading

Berry Corporation Reaffirms a Strong Liquidity Position, Balance Sheet Strength, and Ongoing Free Cash Flow Generation

Written by Customer Service on . Posted in Public Companies.

DALLAS, Aug. 30, 2024 (GLOBE NEWSWIRE) — Berry Corporation (bry) (NASDAQ: BRY) (“Berry” or the “Company”) is reaffirming its strong liquidity position consisting of $94 million of available borrowing capacity under its reserve-based lending (“RBL”) facility and $11 million of cash as of August 23, 2024, as well as its expectation of significant free cash flow generation continuing during the second half of 2024. As of August 23, 2024, the Company’s borrowings outstanding under its RBL facility were $22 million, reflecting a reduction of approximately 57%, or $29 million, since the first quarter of 2024. This reduction included the final payment of $20 million made in July on the 2023 Macpherson transaction. The Company maintains $125 million of available borrowing capacity until the RBL facility matures on August 26, 2025. The...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.